MedTrace Logo

Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles

NCT05520125 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-08-29

No results posted yet for this study

Summary

Treatment of patients with segmental bone tissue defects using mesenchymal stem cells enriched by extracellular vesicles

Conditions

  • Segmental Fracture - Bone Loss

Interventions

BIOLOGICAL

Mesenchymal stem cells enriched by extracellular vesicles

Mesenchymal stem cells enriched by extracellular vesicles

OTHER

Standard treatment of bone defects

Standard surgical treatment of bone defects

Sponsors & Collaborators

  • Belarusian Medical Academy of Post-Graduate Education

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Andrei Hancharou, Dr · Institute for biophysics and cellular engineering NAS of Belarus

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520125 on ClinicalTrials.gov